CBC — The Underestimated Cannabinoid

## What Is CBC?

Cannabichromene – CBC for short – is a non-psychoactive cannabinoid first described in 1966 by Raphael Mechoulam and Yechiel Gaoni, just two years after their groundbreaking isolation of THC. In many cannabis varieties, CBC is the third most abundant cannabinoid after THC and CBD. Particularly in young cannabis plants and tropical landraces, CBC concentrations can be remarkably high.

Like all phytocannabinoids, CBC originates from the common precursor cannabigerolic acid (CBGA). The enzyme CBC synthase converts CBGA into cannabichromenic acid (CBCA), which becomes active CBC through decarboxylation (heat application). The molecular formula of CBC is C₂₁H₃₀O₂ – identical to THC – yet the different spatial arrangement of atoms leads to entirely different pharmacological properties.

## Mechanism of Action

Unlike THC, CBC barely binds to the classical cannabinoid receptors CB1 and CB2. Instead, it interacts with other receptor systems responsible for its biological effects:

TRPV1 and TRPA1 receptors: CBC activates the vanilloid receptors TRPV1 and TRPA1, which are involved in pain perception, inflammation regulation and temperature sensation. Through this mechanism, CBC could exert analgesic and anti-inflammatory effects.

Anandamide reuptake: CBC inhibits the reuptake of the endocannabinoid anandamide, allowing it to remain longer in the synaptic cleft and prolonging its effect. Since anandamide has mood-elevating and anxiolytic properties, this mechanism could explain the antidepressant effect of CBC.

## Research: Anti-Inflammatory Properties

The anti-inflammatory properties of CBC are among the best-studied areas of its effects. A 2010 study published in the British Journal of Pharmacology showed that CBC significantly reduced inflammation in the digestive tract in animal models – via a mechanism independent of the CB1 and CB2 receptors. The combination of CBC with THC showed a stronger anti-inflammatory effect than either substance alone, suggesting a synergistic interaction.

Further preclinical studies indicate that CBC can inhibit the production of pro-inflammatory cytokines and modulate mast cell activation. These findings are particularly relevant for chronic inflammatory conditions where conventional anti-inflammatory drugs often prove insufficient or have significant side effects.

## Research: Antidepressant Effect

A widely cited 2010 study by El-Alfy et al. investigated the antidepressant effects of various cannabinoids in animal models. CBC showed significant antidepressant effects – comparable to those of other cannabinoids but without psychoactive side effects. The authors attributed this effect to the inhibition of anandamide reuptake and the resulting enhancement of endocannabinoid signalling.

These findings are promising but must be confirmed by clinical human studies before therapeutic conclusions can be drawn.

## The Entourage Effect

CBC makes an important contribution to the so-called entourage effect – the phenomenon whereby the overall effect of all cannabinoids, terpenes and flavonoids of a cannabis variety exceeds the sum of their individual effects. In particular, the synergistic effect of CBC with THC and CBD in inflammation reduction and pain relief supports the hypothesis that full-spectrum cannabis products may be therapeutically more effective than isolated individual substances.

## Current Challenges

CBC research is still in its early stages. The majority of studies are based on animal or cell culture models, and clinical human studies are rare. Furthermore, the availability of pure CBC for research purposes is limited, as isolation is complex. However, increasing legalisation and the growing scientific interest in cannabinoids beyond THC and CBD suggest that CBC research will gain significant momentum in the coming years.